View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
Open access

A szerző áttekinti a neuroendokrin daganatoknak az utóbbi években jelentősen kibővült gyógyszeres kezelési lehetőségeit. Tárgyalja azokat a legfontosabb szempontokat, amelyeket a gyógyszeres kezelési terv kialakításakor figyelembe kell venni. Gyógyszeres kezelést rendszerint az előrehaladott stádiumú daganatoknál, valamint a hormontúltermeléssel járó esetekben alkalmaznak. A szomatosztatinanalógokkal 25 éve kezelik a hormontúltermelő daganatos, köztük a carcinoid szindrómás betegeket. Egyre több bizonyíték van arra is, hogy a szomatosztatinanalógok daganatellenes hatással is bírnak, különösen a vékonybél-eredetű, valamint feltételezhetően a pancreaskiindulású jól differenciált (G1/G2) daganatok esetében. Csaknem azonos az indikációs területe az interferonoknak. Jól meghatározható esetekben a citosztatikus kemoterápiának változatlanul helye van ezeknek a daganatoknak a kezelésében. A G1/G2 fokozatú, progresszív pancreas neuroendokrin daganatok esetében streptozotocin- és újabban temozolomidalapú kemoterápia alkalmazható. A G3 neuroendokrin carcinomákban ciszplatin-etopozid kombináció javasolt. A közelmúltban két új célzott gyógyszert, az emlős rapamycin célpont everolimust és a kombinált tirozinkináz-gátló sunitinibet törzskönyvezték a G1/G2 pancreas neuroendokrin daganatok kezelésére. A szerző összegzi a legújabb gyógyszeres kezelési ajánlásokat és algoritmusokat. Röviden bemutatja azokat a fejlesztés alatt álló molekulákat, amelyek további reményt nyújtanak a neuroendokrin daganatok kezelésében. Orv. Hetil., 2013, 154, 1556–1564.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Tóth, M., Prónai, L., Németh, A. M., et al.: Carcinoid tumors. [Carcinoid tumorok.] Orv. Hetil, 2002, 143 (19 Suppl. 2), 1087–1092. [Hungarian]

    Németh A. M. , 'Carcinoid tumors. [Carcinoid tumorok.] ' (2002 ) 143 Orv. Hetil : 1087 -1092.

    • Search Google Scholar
  • Prónai, L., Rácz, K., Tulassay, Z.: Neuroendocrine tumors of the digestive system. [Az emésztőrendszer neuroendokrin daganatai.] Orv. Hetil, 2002, 143 (19 Suppl. 2), 1081–1086. [Hungarian]

    Tulassay Z. , 'Neuroendocrine tumors of the digestive system. [Az emésztőrendszer neuroendokrin daganatai.] ' (2002 ) 143 Orv. Hetil : 1081 -1086.

    • Search Google Scholar
  • Petrányi, A., Bodoky, G.: Drugs for the treatment of neuroendocrine tumours. [Neuroendokrin daganatok gyógyszeres kezelése.] Orv Hetil, 2011, 152, 379–391. [Hungarian]

    Bodoky G. , 'Drugs for the treatment of neuroendocrine tumours. [Neuroendokrin daganatok gyógyszeres kezelése.] ' (2011 ) 152 Orv Hetil : 379 -391.

    • Search Google Scholar
  • Rindi, G., Villanacci, V., Ubiali, A.: Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors. Digestion, 2000, 62 (Suppl. 1), 19–26.

    Ubiali A. , 'Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors ' (2000 ) 62 Digestion : 19 -26.

    • Search Google Scholar
  • Schonhoff, S. E., Giel-Moloney, M., Leiter, A. B.: Minireview: Development and differentiation of gut endocrine cells. Endocrinology, 2004, 145, 2639–2644.

    Leiter A. B. , 'Minireview: Development and differentiation of gut endocrine cells ' (2004 ) 145 Endocrinology : 2639 -2644.

    • Search Google Scholar
  • Pavel, M.: Translation of molecular pathways into clinical trials of neuroendocrine tumors. Neuroendocrinology, 2013, 97, 99–112.

    Pavel M. , 'Translation of molecular pathways into clinical trials of neuroendocrine tumors ' (2013 ) 97 Neuroendocrinology : 99 -112.

    • Search Google Scholar
  • Ramage, J. K., Ahmed, A., Ardill, J., et al.: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut, 2012, 61, 6–32.

    Ardill J. , 'Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) ' (2012 ) 61 Gut : 6 -32.

    • Search Google Scholar
  • Öberg, K., Knigge, U., Kwekkeboom, D., et al.: Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2012, 23 (Suppl. 7), vii124–vii130.

    Kwekkeboom D. , 'Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up ' (2012 ) 23 Ann. Oncol. : vii124 -vii130.

    • Search Google Scholar
  • Kulke, M. H., Anthony, L. B., Bushnell, D. L., et al.: NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas, 2010, 39, 735–752.

    Bushnell D. L. , 'NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas ' (2010 ) 39 Pancreas : 735 -752.

    • Search Google Scholar
  • Jensen, R. T., Cadiot, G., Brandi, M. L., et al.: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology, 2012, 95, 98–119.

    Brandi M. L. , 'ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes ' (2012 ) 95 Neuroendocrinology : 98 -119.

    • Search Google Scholar
  • Janson, E. T., Sørbye, H., Welin, S., et al.: Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol., 2010, 49, 740–756.

    Welin S. , 'Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours ' (2010 ) 49 Acta Oncol. : 740 -756.

    • Search Google Scholar
  • Pavel, M., Baudin, E., Couvelard, A., et al.: ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology, 2012, 95, 157–176.

    Couvelard A. , 'ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary ' (2012 ) 95 Neuroendocrinology : 157 -176.

    • Search Google Scholar
  • Eriksson, B., Klöppel, G., Krenning, E., et al.: Consensus guidelines for the management of patients with digestive neuroendocrine tumors – well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology, 2008, 87, 8–19.

    Krenning E. , 'Consensus guidelines for the management of patients with digestive neuroendocrine tumors – well-differentiated jejunal-ileal tumor/carcinoma ' (2008 ) 87 Neuroendocrinology : 8 -19.

    • Search Google Scholar
  • Strosberg, J.: Neuroendocrine tumours of the small intestine. Best Pract. Res. Clin. Gastroenterol., 2012, 26, 755–773.

    Strosberg J. , 'Neuroendocrine tumours of the small intestine ' (2012 ) 26 Best Pract. Res. Clin. Gastroenterol. : 755 -773.

    • Search Google Scholar
  • Öberg, K.: Biotherapies for GEP-NETs. Best Pract. Res. Clin. Gastroenterol., 2012, 26, 833–841.

    Öberg K. , 'Biotherapies for GEP-NETs ' (2012 ) 26 Best Pract. Res. Clin. Gastroenterol. : 833 -841.

    • Search Google Scholar
  • Rinke, A., Müller, H. H., Schade-Brittinger, C., et al.: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol., 2009, 27, 4656–4663.

    Schade-Brittinger C. , 'Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group ' (2009 ) 27 J. Clin. Oncol. : 4656 -4663.

    • Search Google Scholar
  • Jann, H., Denecke, T., Koch, M., et al.: Impact of octreotide Long-Acting Release on tumour growth control as first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology, 2013 Aug 13., DOI:10.1159/000353785 . PMID 23797176 [Epub ahead of print]

    Koch M. , 'Impact of octreotide Long-Acting Release on tumour growth control as first-line treatment in neuroendocrine tumours of pancreatic origin ' (2013 ) Neuroendocrinology : -.

    • Search Google Scholar
  • Colao, A., Petersenn, S., Newell-Price, J., et al.: A 12-month phase 3 study of pasireotide in Cushing’s disease. N. Engl. J. Med., 2012, 366, 914–924.

    Newell-Price J. , 'A 12-month phase 3 study of pasireotide in Cushing’s disease ' (2012 ) 366 N. Engl. J. Med. : 914 -924.

    • Search Google Scholar
  • Kvols, L. K., Oberg, K. E., O’dorisio, T. M., et al.: Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr. Relat. Cancer, 2012, 19, 657–666.

    O’dorisio T. M. , 'Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study ' (2012 ) 19 Endocr. Relat. Cancer : 657 -666.

    • Search Google Scholar
  • Platanias, L. C.: Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol., 2005, 5, 375–386.

    Platanias L. C. , 'Mechanisms of type-I- and type-II-interferon-mediated signalling ' (2005 ) 5 Nat. Rev. Immunol. : 375 -386.

    • Search Google Scholar
  • Detjen, K. M., Welzel, M., Farwig, K., et al.: Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology, 2000, 118, 735–748.

    Farwig K. , 'Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells ' (2000 ) 118 Gastroenterology : 735 -748.

    • Search Google Scholar
  • Oberg, K.: Endocrine tumors of the gastrointestinal tract: systemic treatment. Anti-cancer Drugs, 1994, 5, 503–519.

    Oberg K. , 'Endocrine tumors of the gastrointestinal tract: systemic treatment ' (1994 ) 5 Anti-cancer Drugs : 503 -519.

    • Search Google Scholar
  • Kouvaraki, M. A., Ajani, J. A., Hoff, P., et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol., 2004, 22, 4762–4771.

    Hoff P. , 'Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas ' (2004 ) 22 J. Clin. Oncol. : 4762 -4771.

    • Search Google Scholar
  • Reid, J. M., Kuffel, M. J., Miller, J. K., et al.: Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin. Cancer Res., 1999, 5, 2192–2197.

    Miller J. K. , 'Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1 ' (1999 ) 5 Clin. Cancer Res. : 2192 -2197.

    • Search Google Scholar
  • Kulke, M. H., Hornick, J. L., Frauenhoffer, C., et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin. Cancer Res., 2009, 15, 338–345.

    Frauenhoffer C. , 'O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors ' (2009 ) 15 Clin. Cancer Res. : 338 -345.

    • Search Google Scholar
  • Ekeblad, S., Sundin, A., Janson, E. T., et al.: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res., 2007, 13, 2986–2991.

    Janson E. T. , 'Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors ' (2007 ) 13 Clin. Cancer Res. : 2986 -2991.

    • Search Google Scholar
  • Hammel, P., Hentic, O., Neuzillet, C., et al.: New treatment options with cytotoxic agents in neuroendocrine tumours. Target. Oncol., 2012, 7, 169–172.

    Neuzillet C. , 'New treatment options with cytotoxic agents in neuroendocrine tumours ' (2012 ) 7 Target. Oncol. : 169 -172.

    • Search Google Scholar
  • Strosberg, J. R., Fine, R. L., Choi, J., et al.: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011, 117, 268–275.

    Choi J. , 'First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas ' (2011 ) 117 Cancer : 268 -275.

    • Search Google Scholar
  • Welin, S., Sorbye, H., Sebjornsen, S., et al.: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, 2011, 117, 4617–4622.

    Sebjornsen S. , 'Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy ' (2011 ) 117 Cancer : 4617 -4622.

    • Search Google Scholar
  • Costa, F. P., Gumz, B., Pasche, B.: Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol., 2012, 26, 843–854.

    Pasche B. , 'Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours ' (2012 ) 26 Best Pract. Res. Clin. Gastroenterol. : 843 -854.

    • Search Google Scholar
  • Alistar, A., Sung, M., Kim, M., et al.: Clinical pathways for pancreatic neuroendocrine tumors. J. Gastrointest. Cancer, 2012, 43, 532–540.

    Kim M. , 'Clinical pathways for pancreatic neuroendocrine tumors ' (2012 ) 43 J. Gastrointest. Cancer : 532 -540.

    • Search Google Scholar
  • Reidy-Lagunes, D., Thornton, R.: Pancreatic neuroendocrine and carcinoid tumors: what’s new, what’s old, and what’s different? Curr. Oncol. Rep., 2012, 14, 249–256.

    Thornton R. , 'Pancreatic neuroendocrine and carcinoid tumors: what’s new, what’s old, and what’s different? ' (2012 ) 14 Curr. Oncol. Rep. : 249 -256.

    • Search Google Scholar
  • Weatherstone, K., Meyer, T.: Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Target. Oncol., 2012, 7, 161–168.

    Meyer T. , 'Streptozocin-based chemotherapy is not history in neuroendocrine tumours ' (2012 ) 7 Target. Oncol. : 161 -168.

    • Search Google Scholar
  • Meric-Bernstam, F., Gonzalez-Angulo, A. M.: Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol., 2009, 27, 2278–2287.

    Gonzalez-Angulo A. M. , 'Targeting the mTOR signaling network for cancer therapy ' (2009 ) 27 J. Clin. Oncol. : 2278 -2287.

    • Search Google Scholar
  • Yao, J. C., Shah, M. H., Ito, T., et al.: Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364, 514–523.

    Ito T. , 'Everolimus for advanced pancreatic neuroendocrine tumors ' (2011 ) 364 N. Engl. J. Med. : 514 -523.

    • Search Google Scholar
  • Bousquet, C., Lasfargues, C., Chalabi, M., et al.: Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J. Clin. Endocrinol. Metab., 2012, 97, 727–737.

    Chalabi M. , 'Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy ' (2012 ) 97 J. Clin. Endocrinol. Metab. : 727 -737.

    • Search Google Scholar
  • Benavent, M., de Miguel, M. J., Garcia-Carbonero, R.: New targeted agents in gastroenteropancreatic neuroendocrine tumors. Target. Oncol., 2012, 7, 99–106.

    Garcia-Carbonero R. , 'New targeted agents in gastroenteropancreatic neuroendocrine tumors ' (2012 ) 7 Target. Oncol. : 99 -106.

    • Search Google Scholar
  • Raymond, E., Dahan, L., Raoul, J. L., et al.: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med., 2011, 364, 501–513.

    Raoul J. L. , 'Sunitinib malate for the treatment of pancreatic neuroendocrine tumors ' (2011 ) 364 N. Engl. J. Med. : 501 -513.

    • Search Google Scholar
  • Akerstrom, G., Falconi, M., Kianmanesh, R., et al.: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology, 2009, 90, 203–208.

    Kianmanesh R. , 'ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors ' (2009 ) 90 Neuroendocrinology : 203 -208.

    • Search Google Scholar
  • Phan, A. T., Oberg, K., Choi, J., et al.: NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas, 2010, 39, 784–798.

    Choi J. , 'NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus) ' (2010 ) 39 Pancreas : 784 -798.

    • Search Google Scholar
  • Yao, J. C., Hassan, M., Phan, A., et al.: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol., 2008, 26, 3063–3072.

    Phan A. , 'One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States ' (2008 ) 26 J. Clin. Oncol. : 3063 -3072.

    • Search Google Scholar
  • Tijeras-Raballand, A., Neuzillet, C., Couvelard, A., et al.: Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Target. Oncol., 2012, 7, 173–181.

    Couvelard A. , 'Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies ' (2012 ) 7 Target. Oncol. : 173 -181.

    • Search Google Scholar
  • Dong, M., Phan, A. T., Yao, J. C.: New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin. Cancer Res., 2012, 18, 1830–1836.

    Yao J. C. , 'New strategies for advanced neuroendocrine tumors in the era of targeted therapy ' (2012 ) 18 Clin. Cancer Res. : 1830 -1836.

    • Search Google Scholar
  • Missiaglia, E., Dalai, I., Barbi, S., et al.: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol., 2010, 28, 245–255.

    Barbi S. , 'Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway ' (2010 ) 28 J. Clin. Oncol. : 245 -255.

    • Search Google Scholar
  • Yao, J. C., Pavel, M., Phan, A. T., et al.: Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J. Clin. Endocrinol. Metab., 2011, 96, 3741–3749.

    Phan A. T. , 'Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus ' (2011 ) 96 J. Clin. Endocrinol. Metab. : 3741 -3749.

    • Search Google Scholar
  • Singh, S., Law, C.: Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev. Gastroenterol. Hepatol., 2012, 6, 313–334.

    Law C. , 'Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors ' (2012 ) 6 Expert Rev. Gastroenterol. Hepatol. : 313 -334.

    • Search Google Scholar
  • Townsend, A., Price, T., Yeend, S., et al.: Metastatic carcinoid tumor: changing patterns of care over two decades. J. Clin. Gastroenterol., 2010, 44, 195–199.

    Yeend S. , 'Metastatic carcinoid tumor: changing patterns of care over two decades ' (2010 ) 44 J. Clin. Gastroenterol. : 195 -199.

    • Search Google Scholar
  • Ito, T., Igarashi, H., Jensen, R. T.: Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J. Gastroenterol., 2012, 47, 941–960.

    Jensen R. T. , 'Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances ' (2012 ) 47 J. Gastroenterol. : 941 -960.

    • Search Google Scholar
  • Modlin, I. M., Gustafsson, B. I., Pavel, M., et al.: A nomogram to assess small-intestinal neuroendocrine tumor (‘carcinoid’) survival. Neuroendocrinology, 2010, 92, 143–157.

    Pavel M. , 'A nomogram to assess small-intestinal neuroendocrine tumor (‘carcinoid’) survival ' (2010 ) 92 Neuroendocrinology : 143 -157.

    • Search Google Scholar
  • Frilling, A., Åkerström, G., Falconi, M., et al.: Neuroendocrine tumor disease: an evolving landscape. Endocr. Relat. Cancer, 2012, 19, R163–R185.

    Falconi M. , 'Neuroendocrine tumor disease: an evolving landscape ' (2012 ) 19 Endocr. Relat. Cancer : R163 -R185.

    • Search Google Scholar
  • Naraev, B. G., Strosberg, J. R., Halfdanarson, T. R.: Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology, 2012, 83, 117–127.

    Halfdanarson T. R. , 'Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors ' (2012 ) 83 Oncology : 117 -127.

    • Search Google Scholar